A new study published in the Journal of Clinical Investigation (JCI) finds treatment with Novocure Ltd's (NASDAQ: NVCR) Tumor Treating Fields (TTFields) mediated cell disruption
NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.10) by 150 percent. This is a 725 percent decrease over earnings of $0.04 per share from the same
Novocure (NASDAQ:NVCR) today announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption activates the